Granted Patent
B2
US 7,494,982 · App. 10/938,184 · Granted Feb 24, 2009
Modified oligonucleotides for telomerase inhibition
Assignee:
Geron Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.
Claims (4)
1. A compound having the structure:
wherein “nps” represents a thiophosphoramidate linkage —NH—P(═O)(SH)—O—, connecting the 3'-carbon of one nucleoside to the 5'-carbon of the adjacent nucleoside;
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a compound according to claim 1 formulated in a pharmaceutically acceptable excipient.
Assignments (2)
PATENT SECURITY AGREEMENT
Recorded Nov 12, 2024
From: GERON CORPORATION
To: BIOPHARMA CREDIT PLC [COLLATERAL AGENT]
Reel/Frame 069341/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 9, 2004
From: GRYAZNOV, SERGEI; PONGRACZ, KRISZTINA
To: GERON CORPORATION
Reel/Frame 015787/0660 →
Continuity (2)
Provisional Application
6050150900
· Sep 9, 2003